Every 8-K that Bolt Biotherapeutics, Inc. (BOLT) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow BOLT and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full BOLT filings page.
Bolt Biotherapeutics reported second quarter 2026 results while emphasizing progress in its lead oncology program. The Phase 1/2 trial of BDC-4182, a first-in-class immune-stimulating antibody conjugate targeting claudin 18.2, is ongoing in gastric and gastroesophageal cancers, with patients now being treated in Cohort 4 at the 4.0 mg/kg dose level. Initial clinical data are expected to be released with the company’s third quarter 2026 results.
Financially, collaboration revenue for the quarter was $5,000 versus $1.8 million a year earlier, reflecting a sharp decline in R&D collaboration activity. Operating discipline offset some of this impact: R&D expenses fell to $5.1 million from $7.5 million and G&A to $2.4 million from $3.5 million, aided by prior restructuring. Net loss for the quarter narrowed to $7.7 million from $8.6 million, and for the first half of 2026 to $15.0 million from $19.6 million. Cash, cash equivalents and marketable securities totaled $18.1 million as of June 30, 2026, which the company expects will fund operations into the first quarter of 2027, while the rest of its pipeline remains on hold pending further progress and partnering.
Bolt Biotherapeutics, Inc. reported the results of its 2026 annual stockholder meeting. Stockholders elected William P. Quinn and Jakob Dupont, M.D. as Class II directors to serve until the 2029 annual meeting or until a successor is chosen.
A total of 1,921,567 common shares were entitled to vote as of April 22, 2026, with 877,358 shares represented in person or by proxy. Stockholders also ratified PricewaterhouseCoopers LLP as the independent registered public accounting firm for the year ending December 31, 2026.
Bolt Biotherapeutics reported first quarter 2026 results and a business update. Collaboration revenue was $26,000 compared with $1.2 million a year earlier as work under R&D collaborations declined. Research and development expenses fell to $4.8 million from $9.5 million, and general and administrative expenses declined to $2.8 million from $3.8 million, reflecting restructuring and lower clinical and research costs. Loss from operations narrowed to $7.6 million, with net loss at $7.2 million.
The company ended March 31, 2026 with $23.9 million in cash, cash equivalents, and marketable securities, which it expects will fund operations into 2027. Bolt’s lead program, BDC‑4182, a first‑in‑class immune‑stimulating antibody conjugate targeting claudin 18.2, is in an ongoing Phase 1/2 trial in gastric and gastroesophageal cancer, with initial clinical data expected in the third quarter of 2026. Other ISAC programs targeting CEA and PD‑L1, and the Dectin‑2 agonist BDC‑3042, remain on hold pending proof‑of‑concept for BDC‑4182.
Bolt Biotherapeutics reported fourth-quarter and full-year 2025 results showing sharply lower operating losses and a more focused pipeline. Full-year loss from operations narrowed to $36.1 million from $73.0 million in 2024 as research and development and general and administrative costs were reduced following restructuring.
Collaboration revenue was $7.7 million for 2025, flat with 2024, with $2.5 million recognized in the fourth quarter. Net loss improved to $33.4 million from $63.1 million a year earlier. Cash, cash equivalents and marketable securities totaled $31.8 million as of December 31, 2025, which the company expects will fund key milestones and operations into 2027.
The lead Boltbody™ ISAC candidate, BDC-4182 targeting claudin 18.2, is in a Phase 1 dose-escalation trial in gastric and gastroesophageal cancers, with initial clinical data expected in the third quarter of 2026. Two additional ISAC programs targeting CEA and PD-L1 remain on hold pending partnering or funding.
Bolt Biotherapeutics (BOLT) furnished an 8-K announcing it issued a press release with financial results for the third quarter ended September 30, 2025 and a corporate update. The press release is attached as Exhibit 99.1 and incorporated by reference.
The company states the information is furnished, not filed, and therefore is not subject to Section 18 liability under the Exchange Act nor automatically incorporated into other SEC filings.
Bolt Biotherapeutics is implementing a major restructuring to cut operating expenses and preserve cash. The company will reduce its workforce by about 20 employees, representing roughly 50% of its staff, and expects pre-tax charges of $1.5 million to $2.0 million for severance, benefits, and related costs. These charges are expected to be recorded in the fourth quarter of 2025, with the reduction-in-force completed by the end of 2025.
The company also provided an update on its ongoing Phase 1 dose escalation study of BDC-4182, a next-generation Boltbody ISAC targeting claudin 18.2. A strong immune response was observed at initial dose levels, and the protocol is being modified to allow step-up dosing, which is supported by preclinical data. Bolt now expects to report initial clinical data in the third quarter of 2026 and states that the workforce reduction is intended to conserve capital and extend its cash runway into 2027.